For in vivo imaging, the mouse was anesthetized with a mixture of zoletil (30 mg/kg) and xylazine (10 mg/kg) by intramuscular injection. Body temperature of the anesthetized mouse was maintained at 36°C by using a homeothermic temperature monitoring and control system (RightTemp; Kent Scientific, Torrington, Connecticut, USA) to prevent the abrupt formation of cold cataract hampering the imaging of retina. Yohimbine (2 mg/kg), antagonist of xylazine, was injected to rescue corneal reflex (blinking reflex) to provide protection from corneal injury or dryness during postanesthesia recovery and stabilization of cardiovascular systems. While corneal reflex was maintained, no spontaneous blinking that disturbed the retinal imaging was achieved. Additional protective measures, including eye ointment and artificial tear to avoid corneal injury, were used with an infrared heating lamp during the recovery state from anesthesia. To visualize the flowing RBCs in the retina, fluorescently labeled RBCs using red fluorophore, DiI (stock no. V-22885; Thermo Fisher Scientific, Waltham, Massachusetts, USA), were intravenously injected (number of RBCs = 4.16 × 107/100 µL) at 12 hours before the intravital imaging. In addition, to simultaneously visualize retinal vasculature, 25 µg anti-CD31 antibody (stock no. 553708; BD Biosciences, Franklin Lakes, New Jersey, USA) conjugated with a far-red color fluorophore, Alexa Fluor 647 (stock no. A20006; Invitrogen, Waltham, Massachusetts, USA), was intravenously injected, which fluorescently labeled endothelial cells of the whole body in a systemic manner. For longitudinal observation of RBC flow velocity changes with aging, intravital imaging of the retina was performed at 3, 4, 8, 14, 18, 22, 32, 42, 60, and 62 weeks old either by repeated imaging of the same mouse or by cross-sectional imaging of individual mice at each time point.